JP2014521089A - 液体試料中のアミロイドベータオリゴマーの検出方法およびその使用 - Google Patents

液体試料中のアミロイドベータオリゴマーの検出方法およびその使用 Download PDF

Info

Publication number
JP2014521089A
JP2014521089A JP2014520229A JP2014520229A JP2014521089A JP 2014521089 A JP2014521089 A JP 2014521089A JP 2014520229 A JP2014520229 A JP 2014520229A JP 2014520229 A JP2014520229 A JP 2014520229A JP 2014521089 A JP2014521089 A JP 2014521089A
Authority
JP
Japan
Prior art keywords
antibody
oligomer
ndpoi
oligomers
assay
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014520229A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014521089A5 (enExample
Inventor
サベージ，メアリー
シユグリユー，ポール
ウオルフ，アビガイル
マキヤンベル，アレクサンダー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of JP2014521089A publication Critical patent/JP2014521089A/ja
Publication of JP2014521089A5 publication Critical patent/JP2014521089A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
JP2014520229A 2011-07-13 2012-07-09 液体試料中のアミロイドベータオリゴマーの検出方法およびその使用 Pending JP2014521089A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161507332P 2011-07-13 2011-07-13
US61/507,332 2011-07-13
PCT/US2012/045886 WO2013009667A1 (en) 2011-07-13 2012-07-09 Method for detection of amyloid beta oligomers in a fluid sample and uses thereof

Publications (2)

Publication Number Publication Date
JP2014521089A true JP2014521089A (ja) 2014-08-25
JP2014521089A5 JP2014521089A5 (enExample) 2015-08-27

Family

ID=47506433

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014520229A Pending JP2014521089A (ja) 2011-07-13 2012-07-09 液体試料中のアミロイドベータオリゴマーの検出方法およびその使用

Country Status (13)

Country Link
US (2) US20130052670A1 (enExample)
EP (2) EP2732289B1 (enExample)
JP (1) JP2014521089A (enExample)
KR (1) KR20140072019A (enExample)
CN (1) CN103782171B (enExample)
AU (1) AU2012282825B2 (enExample)
BR (1) BR112014000671A2 (enExample)
CA (1) CA2840976A1 (enExample)
DK (1) DK2732289T3 (enExample)
ES (1) ES2666840T3 (enExample)
MX (1) MX2014000480A (enExample)
RU (1) RU2014105172A (enExample)
WO (2) WO2013009667A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018526642A (ja) * 2015-08-25 2018-09-13 プロセナ バイオサイエンシーズ リミテッド リン酸化アルファ−シヌクレインを検出するための方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3449926T (pt) 2009-06-17 2019-11-12 Cold Spring Harbor Laboratory Composições e métodos de modulação de excisões de smn2 em um sujeito
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
WO2014110291A1 (en) 2013-01-09 2014-07-17 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of smn2 splicing in a subject
ES2874704T3 (es) * 2013-11-20 2021-11-05 Univ Iowa Res Found Procedimiento para monitorizar la eficacia de un tratamiento de la enfermedad de Alzheimer con una isoforma de ApoE
MA39835A (fr) 2014-04-17 2017-02-22 Biogen Ma Inc Compositions et procédés de modulation de l'épissage du smn2 chez un patient
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
US10436802B2 (en) 2014-09-12 2019-10-08 Biogen Ma Inc. Methods for treating spinal muscular atrophy
MA41480A (fr) * 2014-10-17 2017-12-19 Glenmark Pharmaceuticals Sa Anticorps qui se lient au ccr6 et leurs utilisations
EP3415912B1 (en) 2016-02-08 2023-03-29 Sysmex Corporation Analyte detection method and reagent kit for detecting analyte
US11198867B2 (en) 2016-06-16 2021-12-14 Ionis Pharmaceuticals, Inc. Combinations for the modulation of SMN expression
CN114026109A (zh) * 2019-07-05 2022-02-08 株式会社岛津制作所 β淀粉样蛋白的单克隆抗体、和使用该抗体的β淀粉样蛋白相关肽的测定方法
CN120505310A (zh) 2020-02-28 2025-08-19 Ionis制药公司 用于调节smn2的化合物和方法
WO2022270901A1 (ko) * 2021-06-25 2022-12-29 장재원 동적 형광 또는 x-선의 표준편차와 자기상관을 활용한 조기 진단 시스템
WO2023034324A2 (en) * 2021-08-30 2023-03-09 The Brigham And Women’S Hospital, Inc. Methods and materials to treat neurodegenerative disease
WO2024026413A2 (en) * 2022-07-27 2024-02-01 Durin Technologies, Inc. Early detection and monitoring of neurodegenerative diseases using a multi-disease diagnostic platform
CN117589996A (zh) * 2022-08-09 2024-02-23 深圳智源生物医药有限公司 强毒性淀粉样蛋白寡聚体的诊断用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110166035A1 (en) * 2009-11-24 2011-07-07 Probiodrug Ag Novel diagnostic method

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4665024A (en) 1984-10-01 1987-05-12 Becton, Dickinson And Company Fluorescent gram stain
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US6082205A (en) 1998-02-06 2000-07-04 Ohio State University System and device for determining particle characteristics
DE60043165D1 (de) 1999-08-04 2009-11-26 Univ Southern California Globularer Aufbau vom Amyloid-beta- protein und deren Verwendungen
CN1871517A (zh) * 2002-02-19 2006-11-29 免疫公司 快速有效分离循环癌细胞的方法和试剂
US7807157B2 (en) 2004-02-20 2010-10-05 Intellect Neurosciences Inc. Monoclonal antibodies and use thereof
CA2561532A1 (en) * 2004-04-02 2005-10-20 Merck & Co., Inc. Methods for detecting substances which bind to the amyloid precursor protein or beta amyloid fragments, and binding compounds
US7572640B2 (en) 2004-09-28 2009-08-11 Singulex, Inc. Method for highly sensitive detection of single protein molecules labeled with fluorescent moieties
NZ554725A (en) * 2004-10-25 2009-10-30 Merck & Co Inc Anti-ADDL antibodies and uses thereof
US7731962B2 (en) 2005-02-14 2010-06-08 Merck & Co., Inc. Anti-ADDL monoclonal antibody and use thereof
JP5289963B2 (ja) * 2005-10-21 2013-09-11 メルク・シャープ・アンド・ドーム・コーポレーション 抗ａｄｄｌモノクローナル抗体およびその使用
US20090181359A1 (en) * 2007-10-25 2009-07-16 Lou Sheng C Method of performing ultra-sensitive immunoassays
WO2011151076A2 (en) * 2010-06-04 2011-12-08 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
BR112013000796B1 (pt) * 2010-07-14 2021-08-31 Merck Sharp & Dohme Corp Anticorpo isolado ou um fragmento de ligação ao antígeno, composição farmacêutica, métodos para inibir a montagem de ligantes difusíveis derivados de ß-amiloide, para inibir a fosforilação de proteína tau em ser202/thr205, para identificar um suposto agente terapêutico, para detectar ligantes difusíveis derivados de ß-amiloide e para diagnosticar uma doença associada aos ligantes difusíveis derivados de ß-amiloide, e, kit para detectar ligantes difusíveis derivados de ß-amiloide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110166035A1 (en) * 2009-11-24 2011-07-07 Probiodrug Ag Novel diagnostic method

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018526642A (ja) * 2015-08-25 2018-09-13 プロセナ バイオサイエンシーズ リミテッド リン酸化アルファ−シヌクレインを検出するための方法
JP2021193374A (ja) * 2015-08-25 2021-12-23 プロセナ バイオサイエンシーズ リミテッド リン酸化アルファ−シヌクレインを検出するための方法
JP6989927B2 (ja) 2015-08-25 2022-02-03 プロセナ バイオサイエンシーズ リミテッド リン酸化アルファ－シヌクレインを検出するための方法
JP7244949B2 (ja) 2015-08-25 2023-03-23 プロセナ バイオサイエンシーズ リミテッド リン酸化アルファ－シヌクレインを検出するための方法

Also Published As

Publication number Publication date
AU2012282825A1 (en) 2014-01-16
EP2732289B1 (en) 2018-04-11
WO2013009667A1 (en) 2013-01-17
US20140120037A1 (en) 2014-05-01
ES2666840T3 (es) 2018-05-08
CN103782171A (zh) 2014-05-07
EP2732286A4 (en) 2015-02-25
AU2012282825B2 (en) 2016-05-26
WO2013009703A3 (en) 2013-03-21
WO2013009703A2 (en) 2013-01-17
KR20140072019A (ko) 2014-06-12
CN103782171B (zh) 2016-12-14
RU2014105172A (ru) 2015-08-20
BR112014000671A2 (pt) 2017-02-14
DK2732289T3 (en) 2018-05-22
EP2732286A1 (en) 2014-05-21
WO2013009703A8 (en) 2014-01-23
CA2840976A1 (en) 2013-01-17
EP2732289A2 (en) 2014-05-21
MX2014000480A (es) 2014-06-23
US20130052670A1 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
JP2014521089A (ja) 液体試料中のアミロイドベータオリゴマーの検出方法およびその使用
JP5657382B2 (ja) 高感度イムノアッセイおよび生物学的な目的ペプチドおよびタンパク質の測定用キット
JP2015514206A (ja) 抗ベータアミロイド抗体の検出に関する方法及びキット
WO2011064225A1 (en) Novel diagnostic method for the diagnosis of alzheimer's disease or mild cgnitive impairment
JP2015511014A (ja) アルツハイマー病の診断、予後および監視におけるオリゴマー型Ａβ
US9310383B2 (en) Antibodies, kit and method for detecting amyloid beta oligomers
JP2024001208A (ja) 認知症の診断および／または予測のためのアドレノメデュリン（ａｄｍ）、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー
US20250020669A1 (en) Methods for detecting neurofilament light chain in plasma and cerebrospinal fluid
US20200278358A1 (en) Method of distinguishing between different neurodegenerative diseases
TWI892069B (zh) 用於偵測Tau蛋白或其片段的方法與套組
JP2018501482A (ja) ｐＧｌｕ−Ａｂｅｔａペプチドの検出のための新規の方法
US10295550B2 (en) Compositions and methods for use in diagnosis of alzheimer's disease
WO2026005695A1 (en) Detection of oligomeric tau and soluble tau aggregates
JP2014070037A (ja) アルツハイマー病の診断薬および診断方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150706

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150706

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161115

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170613